Atlas Trials

A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

Clinical trial NCT02329327 · COMPLETED

Trial details

NCT number
NCT02329327
Sponsor
Alexion Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Bleeding
Start date
2015-04-10
Primary completion
2020-09-24
Enrollment
479

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.